Treatment of chronic hepatitis C virus infection via antioxidants: Results of a phase I clinical trial

Journal of Clinical Gastroenterology

Volumn 39, Issue 8, 2005, Pages 737-742

  Melhem, Alla ^a   Stern, Mirela ^a   Shibolet, Oren ^a   Israeli, Eran ^a   Ackerman, Zvi ^a   Pappo, Orit ^a   Hemed, Nilla ^a   Rowe, Mina ^a   Ohana, Hana ^a   Zabrecky, George ^b   Cohen, Robert ^b   Ilan, Yaron ^a,c  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b Marcus Foundation   (United States)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Antioxidants; Hepatitis C; Vitamins

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; GLUTATHIONE; GLYCYRRHIZIC ACID; LIVER ENZYME; PLANT EXTRACT; SCHISANDRA EXTRACT; SILYMARIN; THIOCTIC ACID; UNCLASSIFIED DRUG; VIRUS RNA; VITAMIN B COMPLEX;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIOXIDANT ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DEFECATION DISORDER; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATTY LIVER; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; HYPERALDOSTERONISM; HYPERTENSION; HYPOKALEMIA; IMMUNE RESPONSE; INFLAMMATION; LIPID PEROXIDATION; LIVER BIOPSY; LIVER HISTOLOGY; LIVER NECROSIS; MALE; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PATIENT MONITORING; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; SHORT FORM 36; SIDE EFFECT; VIRUS LOAD;

ADOLESCENT; ADULT; AGED; ANTIOXIDANTS; BIOPSY; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER; MALE; MIDDLE AGED; QUESTIONNAIRES; RNA, VIRAL; TREATMENT OUTCOME;

EID: 23844479925     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mcg.0000174023.73472.29     Document Type: Article

References (50)

1. Schwimmer JB, Balistreri WF. Transmission, natural history, and treatment of hepatitis C virus infection. Semin Liver Dis. 2000;20:37-46.
2. Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis. 2000;20:17-35.
3. Davis GL. Current therapy for chronic hepatitis C. Gastroenterology. 2000;118(suppl 1):104-114.
4. Ferrari C, Urbani S, Penna A, et al. Immunopathogenesis of hepatitis C virus infection. J Hepatol. 1999;31(suppl 1):31-38.
5. Cemy A, Chisari FV. Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence. Hepatology. 1999;3:595-601.
6. Rehermann B, Chisari FV. Cell mediated immune response to the hepatitis C virus. Curr Top Microbiol Immunol. 2000;242:299-325.
7. Vendemiale G, Grattagliano I, Portincasa P, et al. Oxidative stress in symptom-free HCV carriers: relation with ALT flare-up. Eur J Clin Invest. 2001;1:54-63.
8. Tanyalein T, Taskiran D, Topalak O, et al. The effects of chronic hepatitis C and B virus infections on liver reduced and oxidized glutathione concentrations. Hepatol Res. 2000;2:104-109.
9. von Herbay A, Stahl W, Niederau C, et al. Diminished plasma levels of vitamin E in patients with severe viral hepatitis. Free Radic Res. 1996;6: 461-466.
10. Swietek K, Juszczyk J. Reduced glutathione concentration in erythrocytes of patients with acute and chronic viral hepatitis. J Viral Hepatol. 1997;2: 139-141.
11. Barbaro G, Di Lorenzo G, Soldini M, et al. Hepatic glutathione deficiency in chronic hepatitis C: quantitative evaluation in patients who are HIV positive and HIV negative and correlations with plasmatic and lymphocytic concentrations and with the activity of the liver disease. Am J Gastroenterol. 1996;12:2569-2573.
12. Boya P, de la Pena A, Beloqui O, et al. Antioxidant status and glutathione metabolism in peripheral blood mononuclear cells from patients with chronic hepatitis C. J Hepatol. 1999;5:808-814.
13. Berkson BM. A conservative triple antioxidant approach to the treatment of hepatitis C. Combination of alpha lipoic acid (thioctic acid), silymarin, and selenium: three case histories. Med Klin. 1999;94(suppl 3):84-89.
14. Patrick L. Hepatitis C: epidemiology and review of complementary/ alternative medicine treatments. Altern Med Rev. 1999;4:220-238.
15. Luper S. A review of plants used in the treatment of liver disease: part 1. Altern Med Rev. 1998;6:410-421.
16. Schalm SW, Brouwer JT, Bekkering FC, et al. New treatment strategies in non-responder patients with chronic hepatitis. J Hepatol. 1999;31(suppl 1): 184-188.
17. Sinclair S. Chinese herbs: a clinical review of Astragalus, Ligusticum, and Schizandrae. Altern Med Rev. 1998;35:338-344.
18. Marshall AW, Graul RS, Morgan MY, et al. Treatment of alcohol-related liver disease with thioctic acid: a six month randomised double-blind trial. Gut. 1982;12:1088-1093.
19. Eckels DD, Wang H, Bian TH, et al. Immunobiology of hepatitis C virus (HCV) infection: the role of CD4 T cells in HCV infection. Immunol Rev. 2000;174:90-97.
20. Lechner F, Wong DK, Dunbar PR, et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med. 2000; 191: 1499-1512.
21. Cramp ME, Rossol S, Chokshi S, et al. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology. 2000;118:346-355.
22. Liu SL, Degli Esposti S, Yao T, et al. Vitamin E therapy of acute CC14-induced hepatic injury in mice is associated with inhibition of nuclear factor kappa B binding. Hepatology. 1995;22:1474-1481.
23. Sun F, Hamagawa E, Tsutsui C, et al. Evaluation of oxidative stress during apoptosis and necrosis caused by carbon tetrachloride in rat liver. Biochim Biophys Acta. 2001;1535:186-191.
24. Li XJ, Zhao BL, Liu GT, et al. Scavenging effects on active oxygen radicals by schizandrins with different structures and configurations. Free Radic Biol Med. 1990;9:99-104.
25. Yamashiki M, Nishimura A, Suzuki H, et al. Effects of the Japanese herbal medicine 'Sho-saiko-to' (TJ-9) on in vitro interleukin-10 production by peripheral blood mononuclear cells of patients with chronic hepatitis C. Hepatology. 1997;25:1390-1397.
26. von Herbay A, Stahl W, Niederau C, et al. Vitamin E improves the aminotransferase status of patients suffering from viral hepatitis C: a randomized, double-blind, placebo-controlled study. Free Radic Res. 1997; 27:599-605.
27. Nagita A, Ando M. Assessment of hepatic vitamin E status in adult patients with liver disease. Hepatology. 1997;26:392-397.
28. Loguercio C, Caporaso N, Tuccillo C, et al. Alpha-glutathione transferases in HCV-related chronic hepatitis: a new predictive index of response to interferon therapy? J Hepatol. 1998;28:390-395.
29. Sun F, Hayami S, Ogiri Y, et al. Evaluation of oxidative stress based on lipid hydroperoxide, vitamin C and vitamin E during apoptosis and necrosis caused by thioacetamide in rat liver. Biochim Biophys Acta. 2000;1500:181-185.
30. Van Rossum TGJ, Vulto AG, Hop WC et al. Intravenous glycyrrhizin for the treatment of chronic hepatitis C: a double-blind, randomized, placebo-controlled Phase 1/11 trial. Gastroenterol Hepatol. 1999;14:1093-1099.
31. Abe Y, Ueda T, Kato T, et al. Effectiveness of interferon, glycyrrhizin combination therapy in patients with chronic hepatitis. C Nippon Rinsho. 1994;52:1817-1822.
32. van Rossum TG, Vulto AG, de Man RA, et al. Glycyrrhizin as a potential treatment for chronic hepatitis C [Review article]. Aliment Pharmacol Ther. 1998;12:199-205.
33. Arase Y, Ikeda K, Murashima N, et al. The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer. 1997;79:1494-1500.
34. Tsubota A, Kumada H, Arase Y, et al. Combined ursodeoxycholic acid and glycyrrhizin therapy for chronic hepatitis C virus infection: a randomized controlled trial in 170 patients. Eur J Gastroenterol Hepatol. 1999; 11:1077-1083.
35. van Rossum TG, Vulto AG, Hop WC, et al. Pharmacokinetics of intravenous glycyrrhizin after single and multiple doses in patients with chronic hepatitis C infection. Clin Ther. 1999;21:2080-2090.
36. Liu KT, Lesca P. Pharmacological properties of Dibenzo [a,c] cyclooctene derivatives isolated from Fructus Schizandrae Chinensis III. Inhibitory effects on carbon tetrachloride-induced lipid peroxidation, metabolism and covalent binding of carbon tetrachloride to lipids. Chem Biol Interact. 1982;41:39-47.
37. Liu GT. Pharmacological actions and clinical use of fructus schizandrae. Chin Med J (Engl). 1989;102:740-749.
38. Lu H, Liu GT. Effect of dibenzo [a, c] cyclooctene lignans isolated from Fructus schizandrae on lipid peroxidation and anti-oxidative enzyme activity. Chem Biol Interact. 1991;78:77-84.
39. Younes M, Strubelt O. Protection by exogenous glutathione against hypoxic and cyanide-induced damage to isolated perfused rat livers. Toxicol Lett. 1990;50:229-236.
40. Gagliardi B, Fiori GP. Results of a double blind study on the effect of silymarin in the treatment of acute viral hepatitis, carried out at two medical centers. Med Klin. 1978;73:1060-1065.
41. Moscarelli S, Guisti A, Marra F, et al. Therapeutic and anti-lipoperoxidant effects of silybin-phosphatidylcholine complex in chronic liver disease: preliminary results. Curr Ther Res. 1993;53:98-102.
42. Salmi HA, Sarna S. Effect of silymarin on chemical, functional, and morphological alterations of the liver: a double blind controlled study. Scand J Gastroenterol. 1982;17:517-521.
43. Buzzelli G, Moscarella S, Giusti A, et al. A pilot study on the liver protective effect of silybin-phosphatidylcholine complex (1dB 1016) in chronic active hepatitis. Int J Clin Pharmacol Ther Toxicol. 1993;31:456-460.
44. Feher I, Deak G, Muzes G. Liver-protective action of silymarin therapy in chronic alcoholic liver diseases. Orv Hetil. 1989;130:2723-2727.
45. Ferenci P, Dragosics B, Dittrich H, et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol. 1989; 9:105-113.
46. Boigk G, Stroedter L, Herbst H. Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats. Hepatology. 1997;26:643-649.
47. Dehmlow C, Erhard J, deGroot H. Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin. Hepatology. 1996;23:749-754.
48. Bustamante J, Lodge JK, Marcocci L, et al. Alpha-lipoic acid in liver metabolism and disease. Free Radic Biol Med. 1998;24:1023-1039.
49. Houglum K, Venkataramani A, Lyche K, et al. A pilot study of the effects of d-alpha-tocopherol on hepatic stellate cell activation in chronic hepatitis C. Gastroenterology. 1997;113:1069-1073.
50. Meydani SN, Meydani M, Blumberg JB, et al. Vitamin E supplementation and in vivo immune response in healthy elderly subjects: a randomized controlled trial. JAMA. 1997;277:1380-1386.